Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III single-dose etranacogene dezaparvovec trial in adult severe or moderately severe hemophilia B
2017-004305-40Phase 3Active
- Sponsor
- CSL Behring
- Start
- May 2018
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etranacogene dezaparvovec in hemophilia B (HB), sponsored by CSL Behring. Primary endpoint: Annualized bleeding rate comparison for non-inferiority. Started May 2018; status: active.
02
Drugs
etranacogene dezaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2017-004305-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004305-40.